SEC 13F Intelligence

Managers / Q3 2023 · view latest →

5AM Venture Management, LLC

CIK 0001799883 · 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO, CA, 94111 · (415) 993-8565

Reported Value
$348M
Q3 2023
Positions
26
Filings on Record
26
2019–present window
Filed
Nov 14, 2023
original filing

Summary

5am Venture Management, LLC reported $348M in U.S.-listed holdings across 26 positions for Q3 2023.

The portfolio is heavily concentrated: ELVN alone accounts for 20.3% of reported value.

Compared with Q2 2023, the fund opened 2 new positions and exited 0.

Portfolio Metrics

Turnover
+10.0%
vs prior filed quarter
Top-10 Concentration
+74.9%
share of reported value
Largest Position
+20.3%
Enliven Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $465MQ4 ’19Q1 ’20: $323MQ2 ’20: $457MQ3 ’20: $380MQ4 ’20: $297MQ4 ’20Q1 ’21: $555MQ2 ’21: $397MQ3 ’21: $492MQ4 ’21: $533MQ4 ’21Q1 ’22: $458MQ2 ’22: $404MQ3 ’22: $522MQ4 ’22: $372MQ4 ’22Q1 ’23: $391MQ2 ’23: $401MQ3 ’23: $348MQ4 ’23: $377MQ4 ’23Q1 ’24: $447MQ2 ’24: $447MQ3 ’24: $484MQ4 ’24: $419MQ4 ’24Q1 ’25: $264MQ2 ’25: $260MQ3 ’25: $273MQ4 ’25: $318MQ4 ’25Q1 ’26: $360Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 85.6%Other: 14.4%
  • Common Stock · 85.6% · $297M
  • Other · 14.4% · $50M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
DNTHDIANTHUS THERAPEUTICS INCNEW+1.47M1.47M+$20M$20M
TYRATYRA BIOSCIENCES INCNEW+411.4K411.4K+$6M$6M
GH RESEARCH PLCADDED+252.4K404.4K+$2M$4M
VRDNVIRIDIAN THERAPEUTICS INCADDED+130.0K410.0K−$371,800$6M
CRNXCRINETICS PHARMACEUTICALS INTRIMMED−400.0K462.3K−$2M$14M
MLTXMOONLAKE IMMUNOTHERAPEUTICSTRIMMED−44.3K313.2K−$378,816$18M
ELVNENLIVEN THERAPEUTICS INCTRIMMED−637.5K5.16M−$48M$70M
IRONDISC MEDICINE INCTRIMMED−50.0K438.4K−$1M$21M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

26 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ELVNENLIVEN THERAPEUTICS INChistory →COM20.29%$70M5.16M
2TRDAENTRADA THERAPEUTICS INChistory →COM20.04%$70M4.41M
3IRONDISC MEDICINE INChistory →COM5.93%$21M438.4K
4DNTHDIANTHUS THERAPEUTICS INChistory →COM5.79%$20M1.47M
5MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD5.14%$18M313.2K
6CRNXCRINETICS PHARMACEUTICALS INhistory →COM3.96%$14M462.3K
7VOR BIOPHARMA INCCOM3.88%$13M6.36M
8PHARVARIS N VCOM3.53%$12M587.6K
9RALLYBIO CORPCOM3.52%$12M3.63M
10ZNTLZENTALIS PHARMACEUTICALS INChistory →COM2.83%$10M490.0K
11SCPHSCPHARMACEUTICALS INChistory →COM2.46%$9M1.20M
12CLDXCELLDEX THERAPEUTICS INC NEWhistory →COM NEW2.46%$9M310.3K
13MIRATI THERAPEUTICS INCCOM2.41%$8M192.5K
14COGTCOGENT BIOSCIENCES INChistory →COM2.22%$8M790.4K
15VKTXVIKING THERAPEUTICS INChistory →COM1.86%$6M585.0K
16ANABANAPTYSBIO INChistory →COM1.85%$6M357.7K
17VRDNVIRIDIAN THERAPEUTICS INChistory →COM1.81%$6M410.0K
18ARVNARVINAS INChistory →COM1.81%$6M320.0K
19TYRATYRA BIOSCIENCES INChistory →COM1.63%$6M411.4K
20SPRUCE BIOSCIENCES INCCOM1.54%$5M2.36M
21HOMOLOGY MEDICINES INCCOM1.53%$5M4.54M
22AVIDITY BIOSCIENCES INCCOM1.22%$4M665.6K
23GH RESEARCH PLCORDINARY SHARES1.17%$4M404.4K
24MERSANA THERAPEUTICS INCCOM0.48%$2M1.30M
25IMPEL PHARMACEUTICALS INCCOM0.36%$1M2.88M
26CIDARA THERAPEUTICS INCCOM0.31%$1M1.13M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$360M20May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$318M21Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$273M25Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$260M29Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$264M31May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$419M31Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$484M28Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$447M28Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$447M26May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$377M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$348M26Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$401M24Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$391M24May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$372M21Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$522M21Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$404M21Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$458M19May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$533M17Feb 3, 202213F-HRchanges · EDGAR ↗
Q3 2021$492M16Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$397M12Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$555M11May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$297M10Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$380M9Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$457M9Aug 5, 202013F-HRchanges · EDGAR ↗
Q1 2020$323M8Apr 29, 202013F-HRchanges · EDGAR ↗
Q4 2019$465M9Feb 5, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.